Jonathan Hunt MD amp CEO on Q2FY24 amp Firsthalf FY24 results syngene financialresults

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=eklgAg0vt-E

Watch now! Our MD and CEO, Jonathan Hunt, shares his perspective about the Q2 FY24 and First half FY24 performance along with the outlook for the second half of FY24. He covers • ⦿ Our strong performances in Development and Manufacturing Services supported by sustained momentum in the Dedicated Centers • ⦿ Progress on strategic priorities • ⦿ First-half performance characterized by positive contributions from all divisions, and the achievement of several significant strategic goals including: • • The agreement to acquire the multi-modal biologics facility from Stelis Biopharma Ltd. • • The purchase of a 17-acre land parcel in Genome Valley, Hyderabad, as an extension to the existing research campus. • • The regulatory approval from the US Food and Drug Administration (US FDA) for the commercial manufacturing facility in Mangalore. • and more.. • Visit our website to learn more about Syngene and our service offerings; click here 👉 https://bit.ly/3Q7wBmH • #ceospeaks #Q2FY24results #SyngeneQ2FY24results #quarterresults2023 #financialresults

#############################

New on site